Clinical trials: Inflammatory Disorder
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to…
- Trial name
- GARDENIA (NCT02136069)
- Testing
- Etrolizumab, Infliximab
- Where
- 119 sites in Austria, Belgium and 18 more
- Volunteers
- 397 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A in maintaining remission over 52 weeks in adult subjects with Crohn's…
- Trial name
- SHIELD-2 (NCT01316939)
- Testing
- GSK1605786A
- Where
- 256 sites in United States, Australia and 31 more
- Volunteers
- 229 people
- Sponsor
- GlaxoSmithKline
Obesity, Endotoxemia
Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults
This study is focused on assessing gastrointestinal-level improvements by which green tea limits metabolic endotoxemia. It is completed in two phases.
- Conditions
- Obesity, Endotoxemia, Inflammation
- Trial name
- NCT03413735
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Crohn's Disease
A Study of E6011 in Participants With Active Crohn's Disease
The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.
- Trial name
- NCT03733314
- Testing
- E6011
- Where
- 46 sites in Czechia, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- EA Pharma Co., Ltd.
Malaria,Falciparum, Parasitemia
Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
This is a single-centre, open-label, Phase Ib study designed to assess if intravenous injection of approximately 3200 P. falciparum (NF54 strain) sporozoites can be safely administered to achieve blood-stage parasitaemia with a…
- Conditions
- Malaria,Falciparum, Parasitemia, Protozoan Infections, Parasitic Disease
- Trial name
- NCT04310085
- Testing
- Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet, PfSPZ-DVI Challenge
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Inflammatory Bowel Disease
Gene Regulation by Thiazolidinediones
The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon
- Trial name
- GReaT (NCT00567593)
- Testing
- Rosiglitazone
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- James Lewis
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection.
- Trial name
- NCT01482884
- Testing
- tralokinumab
- Where
- 28 sites in Czechia, France and 4 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Crohn's Disease
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).
- Trial name
- NCT00329550
- Testing
- Certolizumab pegol (CZP)
- Where
- 23 sites in Japan
- Volunteers
- 40 people
- Sponsor
- UCB Japan Co. Ltd.
Endometriosis-related Pain, Endometriosis
Enriched Environments in Endometriosis
The investigators propose to conduct a randomized behavioral trial that will produce a clinically useful multi-level integrative medicine model to be used in stress- and inflammation-related disorders that can easily be…
- Conditions
- Endometriosis-related Pain, Endometriosis, Pelvic Pain, Quality of Life
- Trial name
- NCT04179149
- Testing
- Environmental enrichment
- Where
- Puerto Rico
- Volunteers
- 56 people
- Sponsor
- Ponce Medical School Foundation, Inc.
Crohn Disease
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's…
- Trial name
- NCT00094458
- Testing
- infliximab (IFX) infusion; azathioprine (AZA) caps
- Where
- 115 sites in United States, Austria and 13 more
- Volunteers
- 508 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Irritable Bowel Syndrome
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
The purpose of this study is to find whether treating patients with diarrhea predominant Irritable Bowel Syndrome (IBS) with an anti-inflammatory drug called Mesalamine will help improve their symptoms of diarrhea, bloating and…
- Trial name
- IBS (NCT01327300)
- Testing
- Mesalamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Crohn Disease
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index…
- Trial name
- NCT00552058
- Testing
- certolizumab pegol (CDP870, CZP)
- Where
- 116 sites in United States, Australia and 18 more
- Volunteers
- 439 people
- Sponsor
- UCB Pharma
Cognitive Side Effects of Cancer Therapy, Depression
Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness…
- Conditions
- Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- IMPACT (NCT02415387)
- Testing
- typhoid vaccine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, double-blinded, vehicle-controlled, parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GI148512 (benzoyl peroxide [BPO] 3% gel) when applied once daily…
- Trial name
- NCT01400932
- Testing
- GI148512, vehicle gel
- Where
- 19 sites in Japan
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
Bowel Cancer, Bowel Diseases, Inflammatory
LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19
The LumenEye scope and CHiP platform will be piloted in a number of clinical settings including remote colorectal clinics. The rationale is to perform an initial pilot study to determine the clinical utility of the LumenEye…
- Conditions
- Bowel Cancer, Bowel Diseases, Inflammatory, Rectal Bleeding
- Trial name
- LuCID (NCT05043363)
- Testing
- LumenEye X1 digital rectoscope
- Where
- United Kingdom
- Volunteers
- 114 people
- Sponsor
- Imperial College London
Crohn Disease
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
The purpose of this study is to evaluate the efficacy of a treat to target strategy coupled with early endoscopic assessment versus a clinically driven (routine care) approach in achieving endoscopic response.
- Trial name
- STARDUST (NCT03107793)
- Testing
- Ustekinumab
- Where
- 107 sites in Belgium, Czechia and 10 more
- Volunteers
- 500 people
- Sponsor
- Janssen-Cilag Ltd.
Spinal Stenosis, Inflammation
Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion
The aim of the proposed study is to examine the effect of DEX on the inflammatory response in major surgery. More importantly, the investigators will correlate changes in the concentration of inflammatory mediators with…
- Trial name
- NCT01377623
- Testing
- Dexmedetomidine group
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.